FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness

FDA orders new warning on GLP-1s over rare eye condition linked to sudden blindness — Live Feedhttps://www.live-feeds.com/feed/fda-orders-new-warning-on-glp-1s-over-rare-eye-condition-linked-to-sudden-blindnessContinuously updated, source-cited coverage. FDA orders blindness-risk warning on GLP-1 weight-loss drugshttps://www.live-feeds.com/feed/fda-orders-new-warning-on-glp-1s-over-rare-eye-condition-linked-to-sudden-blindnesshttps://www.live-feeds.com/feed/fda-orders-new-warning-on-glp-1s-over-rare-eye-condition-linked-to-sudden-blindness#u197814Thu, 12 Nov 2026 23:22:11 +0000The U.S. Food and Drug Administration has directed manufacturers of popular GLP-1 receptor agonists, including Ozempic, Wegovy, Zepbound and Mounjaro, to add a warning about non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause sudden vision loss. The label change follows reports of NAION in patients using these drugs for diabetes and obesity. The agency says a causal link has not been established but the potential risk warrants disclosure. Drugmakers must update prescribing information and patient medication guides.Why it mattersGLP-1 drugs have become